News & Updates
Showing Multidisciplinary articles
Showing
Show Multimedia Only

Psoriasis patients with overweight, obesity may need higher vunakizumab dosage
14 Oct 2024
byJairia Dela Cruz
In the treatment of moderate-to-severe psoriasis, patients with overweight or obesity appear to have a diminished response to vunakizumab compared with those who have lower BMIs, according to a post hoc subgroup analysis of a phase III trial.
14 Oct 2024

Ebdarokimab works wonders for patients with plaque psoriasis
14 Oct 2024
byStephen Padilla
A recent study has shown the safety and efficacy of AK 101 (ebdarokimab) in the treatment of patients with plaque psoriasis, achieving ≥75-percent improvement in Psoriasis Area and Severity Index (PASI 75) and Static Physicians Global Assessment (sPGA) 0/1 response.
14 Oct 2024

MARIPOSA update: Amivantamab-lazertinib bests osimertinib for EGFRm NSCLC at 3 years
14 Oct 2024
byAudrey Abella
The updated efficacy analysis of the phase III MARIPOSA trial continues to favour amivantamab plus lazertinib over osimertinib for first-line (1L) treatment of patients with EGFR-mutant (EGFRm) advanced non-small cell lung cancer (NSCLC).
14 Oct 2024






